Beyond Risk Launches Unified Health Benefits Funding Platform
Beyond Risk has introduced Beyond Health Partners, a unified health benefits funding platform that consolidates its stop‑loss, captive and cost‑containment businesses. The new platform integrates SL Management Partners, Captive Solutions & Options, and the Beyond Health captive team under one umbrella. It supports both traditional stop‑loss arrangements and alternative funding models such as captives. By offering a single interface, the platform aims to streamline health risk financing for employers and insurers alike.
Evening Update: Inside the CDC’s Collapse Under Political Control.
The article examines how the Centers for Disease Control and Prevention (CDC) has deteriorated under sustained political pressure, highlighting leadership turnover, budget cuts, and the sidelining of scientific expertise. It cites specific instances where political appointees overrode epidemiologists, reshaped data...
Why Listening Is the Core of Patient-Centered Care
Clinicians are increasingly constrained by documentation and tight schedules, leading patients to feel unheard. The article argues that listening is the cornerstone of patient‑centered care, linking empathy to better diagnoses, adherence, and satisfaction. It highlights how electronic health record demands...
Erica Schwartz CDC Nomination: What You Need to Know
President Donald Trump nominated Dr. Erica Schwartz, MD, JD, MPH, as the next CDC Director, pending Senate confirmation. Schwartz, a former Deputy Surgeon General and rear admiral in the Coast Guard, brings two decades of public‑health service and a blend...
Piracetam
Piracetam, the first racetam‑class nootropic developed by Dr. Corneliu Giurgea at UCB Pharma in 1964, remains a cornerstone of cognitive‑enhancement supplements. It modulates AMPA and NMDA glutamate receptors, boosts acetylcholine activity, and increases cerebral blood flow, supporting memory, learning, and...
Why, if After 7 to 21 Years of Follow-Up Data, Disc Arthroplasty Has a Mere 0.67% Index Level Revision Rate,...
A new long-term study of 1,187 lumbar total disc arthroplasty patients, followed for 7 to 21 years, shows durable pain relief and functional improvement. Index‑level revision occurred in only 0.67% of cases, while adjacent‑level surgery was 1.85%. Outcomes were comparable...
New HPV Test Kit for At-Home Use Secures FDA Clearance
The FDA has cleared Waters Corporation’s Onclarity HPV Self-Collection Kit, allowing individuals to collect a vaginal sample at home and send it to a lab for analysis with the BD Onclarity HPV Assay. The kit detects high‑risk HPV strains and...
Bringing AI-Driven Protein-Design Tools to Biologists Everywhere
OpenProtein.AI has launched a no‑code, web‑based platform that gives biologists instant access to powerful protein‑language models and design tools. The suite includes the PoET transformer and its newer PoET‑2 version, which delivers higher accuracy while using a fraction of the...
Anti-Amyloid Alzheimer’s Drugs Show Limited Benefit in Cochrane Review
A Cochrane review of 17 randomized trials involving 20,342 participants found that anti‑amyloid antibodies deliver little to no clinically meaningful improvement in memory, cognition, or dementia severity after roughly 18 months of treatment. The analysis also identified a markedly higher...
Black Maternal Health Week at 10: Preventable Deaths Persist as Black Women Lead the Fight for Change
Marking a decade of Black Maternal Health Week, the United States still sees Black women die at three times the rate of white women from pregnancy‑related causes, with 84% of those deaths deemed preventable. Advocates blame hospital closures, maternity‑care deserts,...
Industry Report: Advanced Therapy Market May Triple by 2030
Cardinal Health’s 2026 Advanced Therapy Report projects that the U.S. advanced therapy market will nearly triple, rising from 61 approved cell and gene treatments today to around 180 by 2030. The study, based on input from 160 physicians and administrators,...
Lawmakers Push for Oral Fluid and Hair Drug Testing
A bipartisan group of six lawmakers urged HHS to overhaul federal drug‑testing rules, arguing that FDA oversight blocks modern methods like oral‑fluid and hair testing. Despite a 2023 DOT final rule permitting oral‑fluid analysis, no U.S. lab is certified, and...
Why Annex 21 Is an Important Commercial Risk Point in EU Market Entry
Charley Maxwell highlights that Annex 21, the EU GMP annex governing medicinal product imports, is more than a paperwork hurdle—it is a commercial risk point that can delay market entry. The annex requires the holder of a Manufacturing Import Authorisation and...
Inside Pharma's Revenue Engine: The Gross-to-Net Reckoning
Model N’s new podcast, Pricing & Policy with Model N, spotlights its annual state‑of‑revenue survey, revealing escalating gross‑to‑net (GTN) complexity across the pharmaceutical sector. Executives discuss how opaque PBM contracts, Medicaid program exits, and coordination‑of‑benefits failures erode net pricing. The conversation also...
What One Spine Patient Risk Factor Drives FIVE Different Adverse Events?
Recent analysis of the ACS NSQIP database examined 2,186 patients aged 65 and older undergoing spinal deformity surgery and evaluated the Geriatric Nutritional Risk Index (GNRI) as a preoperative risk metric. Approximately 20% of these elderly patients were malnourished or...
Top 10 Most Innovative Medical Device Companies in 2026, Per Fast Company
Fast Company’s 2026 list spotlights ten medical‑device innovators reshaping a market that reached $584 billion in 2025. The companies span connected wearables, AI‑driven diagnostics, focused‑ultrasound therapy and minimally invasive tools, reflecting a broader industry shift toward at‑home and less invasive care....
Novel Investment Paradigms for Regenerative Healthcare Ecosystems
The article outlines emerging investment models that aim to fund regenerative healthcare ecosystems, which prioritize prevention, longevity, and environmental sustainability. It highlights decentralized finance, tokenized assets, and blockchain as tools for transparent, multi‑stakeholder capital flows. Venture capital, private equity, blended...
Evercore Maintains Positive Stance on MeiraGTx Holdings Plc (MGTX) Amid Sector Revisions
Evercore ISI analyst Gavin Clark‑Gartner lowered his price target for MeiraGTx Holdings (MGTX) from $20 to $18 while maintaining an Outperform rating, part of a sector‑wide revision of small‑ and mid‑cap biotech firms. The adjustment follows the FDA’s recent Breakthrough...
Morgan Stanley Updates Bicycle Therapeutics Plc (BCYC) Outlook Amid Pipeline Refocus
Morgan Stanley lowered its price target for Bicycle Therapeutics plc (BCYC) to $12 from $13, while maintaining an Equal Weight rating, reflecting a revised valuation after the company refocused its pipeline on BT5528 and next‑generation Bicycle conjugate programs. The shift...
Jefferies Sees Reduced Upside for Arbutus Biopharma Corporation (ABUS) on Higher Appeal Probability
Jefferies lowered its price target for Arbutus Biopharma (ABUS) from $7.00 to $5.50 while keeping a Buy rating, citing a higher probability that Moderna will win its appeal in a patent dispute. The appeal outcome affects a potential $1.3 billion contingent...
Mizuho Sees Strong Risk-Reward in Corbus Pharmaceuticals Holdings, Inc. (CRBP) Near Cash Value
Mizuho Securities raised its price target on Corbus Pharmaceuticals (CRBP) to $40, maintaining an Outperform rating after the company’s fourth‑quarter results. The firm highlighted that CRBP is trading near its cash balance, which it says caps downside risk. Mizuho expects...
Northland Highlights ARS Pharmaceuticals, Inc. (SPRY) Needle-Free Therapy as Major Innovation Driver
Northland Research initiated coverage of ARS Pharmaceuticals (NASDAQ:SPRY) with an Outperform rating and a $25 price target, spotlighting its needle‑free epinephrine spray, Neffy, as a growth catalyst. The U.S. FDA recently revised Neffy’s labeling, removing the previous age restriction and...
Jefferies Sees Reduced Visibility for Replimune Group, Inc. (REPL) Following FDA Decision
Jefferies downgraded Replimune Group (NASDAQ:REPL) from Buy to Hold and slashed its price target to $2 after the FDA issued a complete response letter on the RP1 oncolytic therapy. The FDA’s feedback diverged from earlier Type A meeting guidance, raising...
Evercore Adjusts Fortrea Holdings Inc. (FTRE) Valuation Following Updated Near-Term Assumptions
Evercore ISI trimmed Fortrea Holdings (FTRE) price target to $14 from $25 while keeping an Outperform rating, citing revised near‑term assumptions in its Q1 healthcare technology update. The change coincides with FTRE’s launch of Fortrea Intelligent Technology (FIT), an AI‑enabled...
CMS-0062: An Intra-Agency Cold War Goes Hot
CMS issued two conflicting rules within three weeks, each designating a different HIPAA standard for attaching clinical documentation to payer‑provider transactions. On March 20, 2026, CMS‑0053 finalized X12N 275 as the standard for claim attachments, a long‑awaited adoption. Ten days later, CMS‑0062...
AssureCare CEO on the AI-Powered Platform Unifying Patient Engagement Across Healthcare
AssureCare has launched Aktivate, an AI‑powered patient engagement platform that unifies data, communication channels, and decision‑making across providers, payors, pharmacies, and care teams. The platform orchestrates outreach, using real‑time insights to deliver the right message at the right time and...
Article Intro - White Paper on Surgical Robot Certification
TÜV SÜD has released a detailed white paper on global market entry for surgical robotics, highlighting how the EU Medical Device Regulation now governs these systems and how the forthcoming AI Act will add another compliance layer. The paper outlines...
The World's Most Neglected Disease
A new meta‑analysis of 6.1 million people across 119 countries shows hypertension prevalence has nearly doubled since 2000, with the surge concentrated in low‑ and middle‑income nations. While high‑income regions saw modest declines and control rates rise to 40%, only one...
Friday Hope: Palmitoylethanolamide (PEA): Inhibits Spike Entry, Reduces Proinflammatory Markers in COVID and Improves Symptomology in Long COVID
Recent peer‑reviewed studies demonstrate that palmitoylethanolamide (PEA), a naturally occurring lipid, can block SARS‑CoV‑2 spike protein entry, cut viral replication by roughly 70%, and lower key inflammatory biomarkers in acute COVID‑19 patients. A separate real‑world cohort shows PEA supplementation markedly...
Connecticut Judge Refuses to Hit Pause in Multistate Generic-Drug Antitrust Fight
A federal judge in Connecticut denied a request to pause the multistate antitrust lawsuit accusing generic‑drug manufacturers of price‑fixing. The ruling keeps the coordinated MDL active while settlement discussions continue, preserving litigation pressure on the defendants. The case is a...
Salt Capital and Proparco Acquire Namibian Oncology Centre
Salt Capital and French development finance institution Proparco have jointly acquired The Namibian Oncology Centre (NOC), Namibia’s leading specialist cancer care provider. The acquisition follows NOC’s founding by local clinicians and businesspeople to broaden cancer diagnosis, treatment and care across...
‘Bad-Vaxx’ Game Aims to ‘Inoculate’ Kids Against Vaccine ‘Misinformation’
The "Bad Vaxx" video game, launched last year, uses inoculation theory to teach children to resist vaccine misinformation. Researchers published in Scientific Reports claim the game improves players' ability to spot manipulation and reduces sharing of false content. Funding comes...
Revolution Medicines' Daraxonrasib Cuts Pancreatic Cancer Death Risk by 60% – This Week in Biotech #96
Revolution Medicines announced Phase 3 RASolute 302 results for its oral RAS‑ON inhibitor daraxonrasib in second‑line metastatic pancreatic ductal adenocarcinoma. The trial reported a median overall survival of 13.2 months versus 6.7 months with standard chemotherapy, a hazard ratio of 0.40 and a 60%...
FDA Commissioner Makary: Miracle Cancer Cures Are in the Pipeline
FDA Commissioner Marty Makary has announced that "miracle" cancer cures are on the horizon, promising faster FDA approvals and unprecedented transparency in clinical data. He suggests that trials could be completed within months using thousands of volunteers, dramatically shortening the...
The Quiet Hospital Financial Crisis Threatening Health Care
The article warns that U.S. hospitals are now facing a silent financial crisis, shifting from pandemic‑driven patient surges to cost‑driven strain. Labor expenses stay high, reimbursement lags inflation, and an aging payer mix erodes margins. Service lines are being cut,...
Buckinghamshire Healthcare NHS Trust Becomes First Trust to Sign up to System C’s Ambient AI Consultations
Buckinghamshire Healthcare NHS Trust has become the first NHS organisation to sign a contract with System C to deploy its CareFlow Ambient AI Outpatient Consultations module, slated to go live in summer 2026. The AI‑driven solution will embed real‑time transcription,...
Prescription Drug Costs Soaring Under Trump Regime
A Senate Health, Education, Labor and Pensions Committee report, released by Sen. Bernie Sanders, reveals that drugmakers who signed price‑cut agreements with the Trump administration are simultaneously hiking prices on hundreds of other medications. New therapies now launch at an...
Goodfire AI and the Billion Dollar Bet on Neural Network Interpretability: Why Reverse Engineering Foundation Models Matters for Health Tech...
Goodfire AI, a San Francisco public‑benefit AI lab, raised a $150 million Series B in February 2026, pushing its valuation to $1.25 billion. Its Ember platform gives developers programmatic access to neural‑network internals, claiming a 58% reduction in large‑language‑model hallucinations at roughly 90 × lower...
A Treasure Trove of Food for Thought From Julia Belluz
Julia Belluz’s New York Times essay examines GLP‑1 medicines as broad metabolic tools, not merely weight‑loss drugs. She outlines emerging cardiometabolic, brain‑health, and inflammation benefits while stressing that scientific proof lags behind rapid real‑world adoption. The piece gives weight to patient experiences...
Bringing New Delivery Methods to Treatments: Q&A with Richard Lowenthal
In March 2025 the FDA cleared ARS Pharmaceutical’s neffy, a needle‑free epinephrine nasal spray, marking the first major delivery innovation for the drug in over 35 years. CEO Richard Lowenthal explained that the spray eliminates needle anxiety, simplifies administration, and improves portability,...
The Turning Point for Oral Biologics: Q&A With Morten Graugaard
Orbis Medicines CEO Morten Graugaard says the FDA’s approval of Icotyde validates oral biologics as a viable drug class. He frames the decision as a proof point that macrocycle chemistry can translate biologic efficacy into a pill, but cautions that...
Weekly Neuroscience Update
Researchers unveiled a fully implantable brain‑computer interface that lets paraplegic patients control a robotic exoskeleton with their thoughts, aiming to restore both walking and its sensation. Parallel advances include an AI pruning framework that mimics infant brain development to slash...
Resilience by Design: Building a National Network for Ambulance Services
The Ambulance Radio Programme (ARP) has built a national, dual‑data‑centre network that links 35 NHS trust sites, ensuring 24/7 availability of mission‑critical ambulance communications. Partnering with Vysiion, ARP introduced a dedicated Network Operations Centre and managed services to monitor, patch,...
Woo Truce? The Science and Health Establishment Divided on How to Deal with MAHA and RFK, Jr.
The Trump administration unveiled new meat‑ and milk‑focused dietary guidelines at an event featuring Robert F. Kennedy Jr. and his Make America Healthy Again (MAHA) coalition. AMA President Bobby Mukkamala attended, highlighting the medical community’s split over the administration’s push...
Enough Will They-Won’t They! FDA Pushes for Permanent Rare Pediatric Disease PRVs
The FDA’s FY2027 budget request asks Congress to make the Rare Pediatric Disease (RPD) Priority Review Voucher program permanent, ending its four‑year reauthorization cycle. A voucher lets sponsors shave FDA’s review time from ten to six months and can be...
Trump’s Nominee for CDC Director Likely to Be a Disaster for Vaccine Choice!!
President Trump has nominated retired Rear Admiral Erica Schwartz to lead the Centers for Disease Control and Prevention. Schwartz oversaw the nationwide COVID‑19 vaccine rollout and previously enforced mandatory smallpox, anthrax and flu vaccinations for U.S. service members. Critics argue...
Elon Musk Amplifies Baseless Claim About COVID-19 Vaccine
Elon Musk recently amplified a claim that COVID‑19 vaccines caused tens of thousands of deaths in Germany, a statement that FactCheck.org has debunked as baseless. The claim distorted official vaccine safety monitoring data, suggesting a mortality figure that no German...
How Language Shapes Physician Migration and Medical Training
A recent qualitative survey of medical students from Sudan, Nigeria, Oman and North Africa shows that language, not just salary, determines where physicians can migrate. English‑medium education acts as a professional passport, making the United States, Canada and the United...
Podcast Episode 28: Evaluating and Funding a New Kind of Grant (Clubfoot Treatment)
GiveWell announced a new grant to MiracleFeet to expand free Ponseti clubfoot treatment in low‑ and middle‑income countries, following a site visit in Côte d’Ivoire. The program trains health workers, supplies materials, and educates communities, resulting in hundreds of children...
The Category 2 Peptide Unwind: How a Rogan Appearance, 14 Withdrawn Nominations & a July PCAC Docket Will Reprice the...
Kennedy’s appearance on The Joe Rogan Experience announced that roughly fourteen peptides could be re‑classified from FDA Category 2 back to Category 1, but no Federal Register rule has been issued yet. The announcement highlights a procedural path where nominators withdraw nominations,...